Peptide-Based Therapeutic Vaccines for Allergic Diseases: Where Do We Stand?

  • Hardeep S. Asi
  • Mark Larché
Part of the Allergy Frontiers book series (ALLERGY, volume 6)


In healthy individuals, the immune system is regulated by a variety of mechanisms, which ensure that balance is maintained between inflammatory and anti-inflammatory responses. The diverse repertoire of antigen-specific lymphocytes harbours the potential for the recognition of self, as well as pathogen-derived epitopes and innocuous environmental antigens. In healthy individuals, lymphocyte reactivity is controlled by the central and peripheral tolerance mechanisms. In allergic and autoimmune conditions, however, inappropriate responses are generated as peripheral regulatory mechanisms fail. Disease-modifying therapeutic strategies aim to re-establish homeostasis between effector and regulatory responses. This has been successfully accomplished through allergen-specific immunotherapy (SIT). Despite the clinical efficacy of this form of therapy, it is associated with frequent and potentially life-threatening adverse events which arise primarily as a result of the allergenicity of the treatment preparation. Several strategies to reduce the allergenicity of this form of treatment, whilst maintaining clinical efficacy, are under development. Peptide immunotherapy is one such approach in which synthetic peptides targeting T cell epitopes of the allergen are administered to allergic subjects. Clinical studies have confirmed findings in experimental models, demonstrating the induction of allergen-specific immunological tolerance. The clinical consequences of tolerance induction are discussed herein.


Allergy Clin Immunol Cell Epitope Allergen Challenge Allergen Immunotherapy Late Asthmatic Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Floistrup H, Swartz J, Bergstrom A, Alm JS, Scheynius A, van HM, Waser M, Braun-Fahrlander C, Schram-Bijkerk D, Huber M, Zutavern A, von ME, Ublagger E, Riedler J, Michaels KB, Pershagen G. The Parsifal Study Group. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006; 117:59–66CrossRefPubMedGoogle Scholar
  2. 2.
    Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567–75CrossRefPubMedGoogle Scholar
  3. 3.
    Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392–7CrossRefPubMedGoogle Scholar
  4. 4.
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251–6CrossRefPubMedGoogle Scholar
  5. 5.
    Cookson W. Genetics and genomics of asthma and allergic diseases. Immunol Rev 2002; 190:195–206CrossRefPubMedGoogle Scholar
  6. 6.
    von ME. Allergies, infections and the hygiene hypothesis--the epidemiological evidence. Immunobiology 2007; 212:433–9CrossRefGoogle Scholar
  7. 7.
    Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911–20CrossRefPubMedGoogle Scholar
  8. 8.
    Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103:175–83CrossRefPubMedGoogle Scholar
  9. 9.
    Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004; 199:1679–88CrossRefPubMedGoogle Scholar
  10. 10.
    Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA, Robinson DS. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608–15CrossRefPubMedGoogle Scholar
  11. 11.
    Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immuno-therapy. Nat Rev Immunol 2006; 6:761–71CrossRefPubMedGoogle Scholar
  12. 12.
    Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357:752–6CrossRefPubMedGoogle Scholar
  13. 13.
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468–75CrossRefPubMedGoogle Scholar
  14. 14.
    Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205–14CrossRefPubMedGoogle Scholar
  15. 15.
    Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472–82Google Scholar
  16. 16.
    Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356–65CrossRefPubMedGoogle Scholar
  17. 17.
    Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644–51CrossRefPubMedGoogle Scholar
  18. 18.
    Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178:2123–30CrossRefPubMedGoogle Scholar
  19. 19.
    Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007–15CrossRefPubMedGoogle Scholar
  20. 20.
    Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, Durham SR. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105:56–62CrossRefPubMedGoogle Scholar
  21. 21.
    Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98:1676–83CrossRefPubMedGoogle Scholar
  22. 22.
    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255–61CrossRefPubMedGoogle Scholar
  23. 23.
    Nasser S, Ying S, Meng Q, Kay AB, Ewan P. Interleukin 10 levels increase in cutaneous biopsies of patients undergoing venom immunotherapy. Eur J Immunol 2001; 31:3704–13CrossRefPubMedGoogle Scholar
  24. 24.
    Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252–9PubMedGoogle Scholar
  25. 25.
    Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97–101CrossRefPubMedGoogle Scholar
  26. 26.
    Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microen-vironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13:603–9PubMedGoogle Scholar
  27. 27.
    Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11:S69–S76CrossRefPubMedGoogle Scholar
  28. 28.
    Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983; 157:1434–47CrossRefPubMedGoogle Scholar
  29. 29.
    Counsell CM, Bond JF, Ohman JL, Greenstein JL, Garman RD. Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. J Allergy Clin Immunol 1996; 98:884–94CrossRefPubMedGoogle Scholar
  30. 30.
    Mark PG, Segal DB, Dallaire ML, Garman RD. Human T and B cell immune responses to Fel d 1 in cat-allergic and non-cat-allergic subjects. Clin Exp Allergy 1996; 26:1316–28CrossRefPubMedGoogle Scholar
  31. 31.
    Norman PS, Ohman JL, Jr., Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623–8PubMedGoogle Scholar
  32. 32.
    Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998; 101:506–13CrossRefPubMedGoogle Scholar
  33. 33.
    Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, Yssel H, Bousquet J. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998; 102:571–8CrossRefPubMedGoogle Scholar
  34. 34.
    Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937–45CrossRefPubMedGoogle Scholar
  35. 35.
    Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93:222–31CrossRefPubMedGoogle Scholar
  36. 36.
    Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167:1734–9PubMedGoogle Scholar
  37. 37.
    Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47–53CrossRefPubMedGoogle Scholar
  38. 38.
    Alexander C, Ying S, Kay B, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35:52–8CrossRefPubMedGoogle Scholar
  39. 39.
    Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269–74CrossRefPubMedGoogle Scholar
  40. 40.
    Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immuno-therapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy 2004; 59:1097–101CrossRefPubMedGoogle Scholar
  41. 41.
    Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2:e78CrossRefPubMedGoogle Scholar
  42. 42.
    Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unre-sponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004; 20:695–705CrossRefPubMedGoogle Scholar
  43. 43.
    Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immu-notherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747–54CrossRefPubMedGoogle Scholar
  44. 44.
    Texier C, Pouvelle S, Busson M, Herve M, Charron D, Menez A, Maillere B. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000; 164: 3177–84PubMedGoogle Scholar
  45. 45.
    Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larche M. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465–74CrossRefPubMedGoogle Scholar
  46. 46.
    Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, Corradin G, Spertini F. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:854–61CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Hardeep S. Asi
    • 1
  • Mark Larché
    • 1
  1. 1.Division of Clinical Immunology and Allergy, Department of MedicineMcMaster UniversityHamiltonCanada

Personalised recommendations